Other parameters, such as age, AML type (secondary vs. de novo), cytogenetics risk group, FLT3-ITD or c-KIT D816V mutation status also appeared to be significant predictors of clinical outcomes (Table 3). Here, KIT is linked to acute myeloid leukemia.